Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 07 2024 - 5:01PM
Business Wire
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage
biopharmaceutical company focused on the development and
commercialization of seralutinib for the treatment of pulmonary
arterial hypertension (PAH) and pulmonary hypertension associated
with interstitial lung disease (PH-ILD), today announced that the
Compensation Committee of Gossamer’s Board of Directors approved
the grant, effective October 4, 2024, to five new non-executive
employees of non-qualified stock option awards to purchase up to an
aggregate of 221,000 shares of the Company’s common stock under the
Gossamer Bio, Inc. 2023 Employment Inducement Incentive Award Plan
(“2023 Inducement Plan”). The awards were granted as an inducement
material to the employees entering into employment with Gossamer in
accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.07 per share, which is
equal to the closing price of Gossamer’s common stock as reported
by The Nasdaq Global Select Market on October 4, 2024. The options
have a ten-year term and will vest over four years, with 25%
vesting on the one-year anniversary of the applicable vesting
commencement date and the balance of the shares vesting in a series
of 36 successive monthly installments thereafter, subject to each
employee’s continued employment with Gossamer on such vesting
dates. The options are subject to the terms and conditions of the
2023 Inducement Plan and the terms and conditions of a stock option
agreement covering the grants.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company
focused on the development and commercialization of seralutinib for
the treatment of pulmonary hypertension. Its goal is to be an
industry leader in, and to enhance the lives of patients living
with, pulmonary hypertension.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241007084198/en/
For Investors and Media: Bryan Giraudo, Chief Operating
Officer and Chief Financial Officer Gossamer Bio Investor Relations
ir@gossamerbio.com
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Nov 2024 to Dec 2024
Gossamer Bio (NASDAQ:GOSS)
Historical Stock Chart
From Dec 2023 to Dec 2024